Business
Tonix Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational Medicine
NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical
About this update from Tonix Pharmaceuticals Holding Corp.
[{"type":"text","content":"NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Herbert Harris, M.D., Ph.D., as its new Executive Vice President, Translational Medicine, effective May 15, 2020. In this role, Dr. Harris will focus on advancing Tonix’s pre-clinical pipeline, including the potential COVID-19 vaccine into the clinic, as well as participate in Tonix’s ongoing clinical programs.\n Dr. Gregory Sullivan, Chief Medical Officer of Tonix said, “The recruitment of Dr. Harris to our management team is opportune, arriving at a time Tonix has launched its COVID-19 program and expanded its pipeline of clinical candidates including those in addiction, mood disorders, and geriatric psychiatry. Dr. Harris’ career has exemplified the translational tradition of bringing bench to bedside, with extensive training and research in our Nation’s premier academic and National Institutes of Health (NIH) intramural programs. Moreover, he has applied that expertise to pharmaceutical drug development in industry for many years, and thus brings to Tonix a wealth of experience advancing therapeutics in critical underserved areas that align well with our mission. He will be an asset to both our management team and to the development of our pipeline as Tonix advances its therapeutics, with the goal of ultimately delivering much needed therapeutics for the benefit of patients.” “It’s exciting to join a company with such an experienced management team and sense of purpose towards finding treatments for underserved populations,” said Dr. Harris. “Developing the COVID-19 vaccine is particularly exciting because T cell immunity has been a great interest since my doctoral work. I believe T cell immunity, and particularly TH1 type immunity, will be important in protecting against serious COVID-19 disease and in clearing the virus. Clearing the virus, which I believe requires CD8 T cell immunity in similar viral illnesses, will be important to decreasing forward transmission. I look forward to offering my capabilities and strategic mindset to the Tonix team as the company continues to grow and progress its pipeline.” Dr. Harris earned his M.D. and Ph.D. degrees from the University of Pittsburgh. Dr. Harris’ Ph.D. work in immunology involved...